Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Quality Index
Contineum Therapeutics, Inc. Class A Common Stock cash flow quality index. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Quality Index of 0.98x as of June 2023. Operating cash flow of $40.67 Million is below net income of $41.56 Million, suggesting accrual-heavy earnings not yet converted to cash. See CTNM financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Cash flow quality index of Contineum Therapeutics, Inc. Class A Common Stock from 2023 to 2023. Historical Cash Flow Quality Index for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Contineum Therapeutics, Inc. Class A Com (CTNM) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Quality Index by Year (2023–2023)
Contineum Therapeutics, Inc. Class A Common Stock cash flow quality index by year from 2023 to 2023. Year-by-year earnings quality comparison for Contineum Therapeutics, Inc. Class A Common Stock. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com (CTNM) cash conversion ratio.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 0.85x | $19.35 Million | $22.72 Million | — |